Ann: Imagion Biosystems December 2021 Investor Newsletter, page-17

Mr Market has interpreted the Newsletter today positively. I presume its the same interpretation I have, that is, upgrading USA facilities to ramp-up nanoparticle production, the recent two high level USA appointments clearly in my view screaming out that we will eventually advance to the proposed USA based Phase 2 trials. In support of this also we are told they are pleased with the current trial progress and that the trials on the "multiple" enrollees have been completed, as would be expected given the tests on each individual extend for 1 month only as per the ANZCTR protocol. Can only presume there are no adverse medical issues in light of all this.